Fosinopril/hydrochlorothiazide

Fosinopril/hydrochlorothiazide

Combination of
Fosinopril	Angiotensin converting enzyme inhibitor
Hydrochlorothiazide	Thiazide diuretic
Clinical data
Trade names	Monopril HCT
Pregnancy category	C (1st trimester); D (2nd & 3rd trimesters)
Routes of administration	Oral
ATC code	C09BA09 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)

Fosinopril/hydrochlorothiazide is the combination preparation of fosinopril, an angiotensin converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic. It is a combination drug to treat high blood pressure (hypertension) The other similar drug in UAS is Losartan/hydrochlorothiazide (Hyzaar).

This drug has a boxed warning about its significant risk to cause fetal/neonatal morbidity and mortality when being used during pregnancy (2nd and 3rd trimesters).

FDA modified its labeling on February, 2009 to include a precaution of drug interaction with gold. "Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including MONOPRIL/ MONOPRIL HCT."

Dosage

The recommended initial dosage of Fosinopril/hydrochlorothiazide for adults with high blood pressure (hypertension) is losartan-hydrochlorothiazide 10 mg/12.5 mg per day. The dosage range could be 10-80 mg/12.5-50 mg once a day. When CrCl < 30 mL/min or serum creatinine ≥ 3 mg/dL, patient should not use this drug. Since metabolism of active metabolite fosinoprilat will be reduced in progressive liver disease, patient with hepatic impairment should use this drug with caution.